Exelixis Inc (EXEL)

15.68
-0.16(-1.01%)
After Hours
15.66
-0.02(-0.13%)
- Real-time Data
  • Volume:
    2,923,935
  • Day's Range:
    15.65 - 16.17
  • 52 wk Range:
    15.50 - 23.40

EXEL Overview

Prev. Close
15.84
Day's Range
15.65-16.17
Revenue
1.55B
Open
15.85
52 wk Range
15.5-23.4
EPS
0.856
Volume
2,923,935
Market Cap
5.05B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,085,952
P/E Ratio
21.62
Beta
0.602
1-Year Change
-23.22%
Shares Outstanding
321,831,784
Next Earnings Date
Nov 02, 2022
What is your sentiment on Exelixis?
or
Market is currently closed. Voting is open during market hours.

Exelixis Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Exelixis Inc Analysis

Exelixis Inc Company Profile

Exelixis Inc Company Profile

Employees
954

Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Read More

Analyst Price Target

Average27.15 (+73.17% Upside)
High35
Low18
Price15.68
No. of Analysts13
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • Market Mìracle advisor has published a BUY signal with target 21.358
    0
    • 🚀🚀🚀FDA approves Exelixis thyroid cancer treatment
      1
      • Dog
        0
        • Patricio, acaso vives en Valencia, España? Es que conozco a un Patricio Garnica x'D
          0
      • Exel was supposed to be a great investment. I hope it goes to 30 like expected
        0
        • Any update on this one?
          0
          • Great balance sheet, this stock seems quite undervalued! Just added some more to my portfolio at $19 :D
            1
            • Good report! I think time to buy!
              0
              • president and CEO are selling their shares right before earning report. ain't good
                0
                • Going to the place it belongs, up!
                  0
                  • Nothing, should be forgotten in any portfolio
                    1